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A Role for the Measles Virus in 
Oncology
Daniel Benharroch
Abstract
An association between the measles virus (MV) and classic Hodgkin lymphoma 
(CHL) was reported by our center in Beer-Sheva, starting in 2003. Our basic 
evidence on the relationship had been established by immunohistochemistry, using 
several commercial and specific experimental anti-measles antibodies in about 50% 
of our patients. It relied also on the reverse transcriptase-polymerase chain reaction 
(RT-PCR) and in situ hybridization (ISH) of MV RNA, and overall, was essentially 
descriptive. The first and only response to our thesis was advanced in 2007 in 
doublet articles, in a single issue of a Cancer Journal. Our conclusions were hereby 
dismissed. Since reservations relating the above refutation seemed self-evident, 
the subsequent publication of several of our articles was launched. They disclosed 
evidence of an association of the MV with further categories of cancers, as well as 
its absence in some distinct tumors. A mechanism by which the MV may regulate 
apoptosis in the tumor cells of CHL was also proposed. A suspected role for the 
MV in oncomodulation is advocated. We deplore, however, the absence of further 
interest in our hypothesis among world experts.
Keywords: classic Hodgkin lymphoma, measles virus, antigens, RT-PCR, 
in situ hybridization, endometrial carcinoma, breast cancer, lung cancer
1. Introduction
Classic Hodgkin lymphoma (CHL) stands out among malignant tumors, by the 
relative paucity of the tumor cells in the involved lymph nodes. These Hodgkin and 
Reed-Sternberg (H/RS) cells (Figure 1) are distributed unevenly within the major-
ity of inflammatory cells, fibrosis and necrosis [1]. It is understood that, indepen-
dent of the proportion of H/RS cells in CHL, the outcome of the malignancy will be 
favorable, with a cure rate of 75–90% [2, 3]. Such a therapeutic success is unusual 
for cancer at large.
When considering the many prognostics and risk factors regarding CHL, the 
stage of the tumor, as expected, is the most relevant. Evidence of systemic symp-
toms: fever higher than 38°C for at least a month; weight loss of more than 10% of 
body weight, lasting 6 months or more, and/or drenching night sweats, singly or 
collectively, worsen the prognosis [1]. A difference is described between genders, 
as females fare as a rule better than males, no consideration being given to a higher 
incidence of nodular sclerosis CHL in females. Indeed, children and older adult 
males with mixed cellularity CHL, especially in developing countries, get on worse 
with the disease [2, 4]. In contrast, females would be included in the bulk of CHL 
patients, aged 15–36, with a favorable outcome [5].
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Some 15-20% of human cancers are thought to arise by mechanisms which 
concern viruses, bacteria, or parasites [6, 7]. Evidence for their involvement comes 
partly from the detection of the microorganism in biopsies and partly from epidemio-
logical and animal studies. Viruses might modify cellular genes directly, as with RNA 
tumor viruses, or may affect cell proliferation, as with DNA tumor viruses, and thus 
contribute to neoplasm formation [6, 7]. As a rule, the virus is responsible for only 
a limited number of steps in the promotion or progression of cancer. In most cases, 
the precise role of cancer-associated virus is hard to decipher, due to the long delay 
from the initial viral infection [6]. In any case, the number of human beings infected 
with the above viruses is much larger by far from that of patients who develop cancer. 
Therefore, tumor viruses probably act in conjunction with additional factors [7].
Chronic inflammation may play an important role in the above processes as 
well as in other pathologic events which may lead to cancer [8]. In some cases of 
unresolved chronic inflammation, the immune response becomes maladaptive, 
hence promoting tumorigenesis [8]. A regenerative process supported by an array 
of bioactive mediators, promote cell survival, tissue remodeling, and angiogenesis. 
The mediators will also cause genomic stress and mutations [9].
A correlation between CHL and the Epstein-Barr virus (EBV) has been demonstrated 
many years ago [10, 11], with a causal relationship being established as soon as 2001 [12]. 
The incidence of EBV infection in CHL has shown a wide geographic variation, from 17 
to 30% in industrialized countries, to as high as 100% in some developing countries [13, 14].  
Several more years elapsed before the distribution of EBV infection by gender, age, and 
CHL type was determined (Figure 2) [13, 14]. Thus, EBV is expressed more frequently 
in males, notably in children from developing countries, as well as in older adults all 
over the globe, these two groups showing as a rule mixed cellularity CHL. Female CHL 
patients stand out, in general, by showing nodular sclerosis CHL with a markedly lower 
level of EBV expression and a young adult age (15–36) [15]. A small subset of young 
adult males will develop CHL after recovering from infectious mononucleosis [16]. The 
EBV is recognized as oncogenic. Specifically, its transforming potential, with cell pro-
liferation, inflammation, and apoptosis arrest, has been related to the nuclear factor-κB 
(NF-κB) and the EBV/LMP1 will further contribute to the inhibition of the H/RS cell 
apoptosis [15–19]. As noted, EBV does not play a significant role in the largest subset of 
CHL that affect young adults and most of the female CHL patients.
Figure 1. 
Section of lymph node from a patient with classic HL. Off center is a Hodgkin/Reed-Sternberg giant tumor cell 
(H&E × 360).
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The above subset of young adult female patients corresponds to that defined in 
the hallmark epidemiological studies in the early 1980s as patients with the “late 
host response model” [15–19]. These patients are considered to be submitted to the 
late exposure to a common infectious agent, the term “late” meaning that instead of 
coming across the common infectious agent for the first time in early childhood, this 
occurs at adolescence or young adulthood. The epidemiological thesis further sug-
gests that these individuals had a late encounter with the agent, since they had few 
and late contacts with other children (single child, individual family house, and child 
who skipped the kindergarten) [15]. To account for the late host response model, it is 
suggested that a common agent, probably a virus, reaches the organism for the first 
time at a stage in which the metabolism and/or the hormonal balance is markedly 
different from that of a toddler, the age at which the encounter regularly takes place. 
At this point, the internal environment has varied deeply and probably, so has the 
immune system [15–19]. Thus, it seems that the EBV plays a relatively minor role, in 
the largest subset of the CHL that is most prevalent in industrialized countries [18].
When looking for a substitute for the EBV in CHL, it was observed that none of 
the additional viruses, HHV-6, -7, -8, polyoma JC virus, SV40, HTLV-1 and -2, and 
human retrovirus 5, once considered as possible candidates, have been detected in 
CHL tissues [20–26]. The only virus to be incompletely excluded at that time was 
the HCMV. However, one distinct virus showed qualities and associations which 
recalled to various extents of those of CHL.
The “candidate” proposed by us is the measles virus (MV). It penetrates the 
organism through the oropharynx. But, since it is lymphotropic, it enters the 
adjacent lymphoid tissues. This may account for the vast majority of CHL starting 
in cervical and/or in mediastinal lymph nodes [12, 27]. Histologically, it elaborates 
multinucleated cells—the Warthin-Finkeldey polykaryons. Of note, these polykary-
ons differ largely from the H/RS cells of CHL, mainly by the number of nuclei 
(up to 70) as well as by their phenotype (they are T-lymphocytes) [28]. An acute 
measles infection is soon followed, on the one hand by a life-long specific immu-
nity, but also, paradoxically a transient cellular immune deficiency systematically 
develops. This deficiency lasts about 6 months, but at times, may last longer. The 
cellular immune deficiency which affects CHL patients is not different in principle, 
but it may be long lasting [12].
Figure 2. 
Association between age, gender, EBV expression, and classic Hodgkin lymphoma, including the types thereof.
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At the time our thesis was formulated, the type of MV neural infection known 
as subacute sclerosing panencephalitis (SSPE) was considered one of the very few 
persistent MV infections, most being CNS slow viral infections. However, it was 
difficult to grasp a possible association between MV and cancer, which would not 
account for the long lapse of time necessary for the malignant transformation. In 
that context, the absence of a persistent MV infection might be counterproductive. 
The alternative being that against all odds, MV may be oncogenic, and the MV is 
not among the consensually recognized oncogenic viruses! An additional clue to 
MV causing a persistent infection beyond the CNS is the absence of membrane 
expression of hemagglutinin MV antigens, although this lack of expression might 
be due also to the lymph node mode of fixation [29].
2. Materials and methods
The basic part of our study (2003–2004) concerned 154 patients with CHL 
diagnosed between 1975 and 2000 at the Soroka University Medical Centre in Beer-
Sheva, Israel, whose tissues were available for research. Only pretreatment biopsies 
with confirmed histological type, by two hematopathologists were included. 
Clinical data were retrieved from the patients’ charts and when those were not 
found, the details were searched in the Israel Population Registry by linkage.
2.1 Immunohistochemistry
Immunophenotyping was performed on formalin-fixed, paraffin-embedded 
(FFPE) tissues by the avidin-biotin peroxidase complex method and the 
Vectastain kit by Vector Laboratories (Burlingame, CA, USA) as described. 
The EBV/LMP1 antibody was purchased from Dako (Glostrup, Denmark); the 
anti-MV antibodies were either commercial: anti-nucleoprotein (NP)-MV; anti-
hemagglutinin (HA)-MV; anti-matrix (M)-MV; and anti-phosphoprotein (P)-MV 
were purchased from Chemicon International Inc. (Temecula, CA, USA). Further 
experimental antibodies were a gift from Birrer et al. [30]: anti-NP, H14; and from 
Schneider-Schaulies et al. [31]: anti-NP, L39/22; L39/61 or anti-HA antibodies, 
K83; L77. The antibody specificity had been demonstrated by Western blotting. 
The staining was considered positive if 10% of H/RS cells or more were positive. 
For stringency purposes, we requested positivity for two MV antigens, for a case 
to be considered positive. A murine neuroblastoma cell line permanently infected 
by MV was used as a positive control; the same cell line, but non-infected was 
used as a negative control. These cell lines were also the controls used for the 
RT-PCR and ISH assays. Twenty-five cases of non-Hodgkin lymphoma were also 
tested by IHC.
2.2 Reverse transcriptase-polymerase chain reaction
Total RNA was obtained by extraction of snap-frozen lymph node samples from 
part of our patients, when available. For this goal, EZ-RNA Total RNA Isolation Kit 
(Biological Industries Co., Beit Ha-Emek, Israel) was employed, using the manufac-
turer’s instructions. To each sample, 40 U of RNA-guard (Promega, Madison, WI, 
USA) were added. One step RT-PCR was performed with Ready To Go ™ RT-PCR 
beads (Amersham Pharmacia Biotech Europe GbmH, Freiburg, Germany). A mea-
sure of 3 μl of RNA (2-6 μg) was used for each reaction. For the primers used in this 
study, see Table 1 from Ref. [3]. Nested PCR was carried out, using SUPER-NOVA 
DNA polymerase (Roche Molecular Biochemicals, Mannheim, Germany).
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Total RNA was also retrieved from several FFPE tissues from CHL patients, 
using the Paraffin Block RNA Isolation Kit (Ambion Inc., The RNA Company, 
Austin, TX. USA) and RT-PCR followed by nested PCR carried out with 10 μl RNA, as 
described above. As controls, we used seven cases of non-Hodgkin lymphomas, one 
CHL which was negative for MV by IHC. As housekeeping genes, we used β-actin 
and protein phosphatase 2C β (pp2Cβ) considered appropriate for experiments 
related with low amounts of RNA.
To confirm our RT-PCR findings, the cDNA products of the nested PCR were 
blotted to GeneScreen (NEN Research Products, Boston, MA, USA) and hybridized 
to either an NP-MV probe (CAATCCCTGGAGATTCCTCA) or to a HA-MV probe 
(GCTGGAAGCTGACACCTTTC), labeled [γ-32 P] ATP (Amersham).
2.3 In situ hybridization on paraffin sections
The digoxigenin (DIG)-labeled antisense and sense probes to MV-specific 
mRNAs were prepared by linearizing the plasmids containing NP-MV including 
positions 105–586, and those including HA-MV encompassing positions 8147–
8482 in PGEM-T Easy Vectors (Promega), with SalI or SacII. In vitro transcription 
was performed with the DIG-RNA Labeling kit, with SP6 for NP antisense and HA 
sense probes and T7 for NP sense and HA antisense DIG-labeled probes. The quality 
of the probes was determined by dot blotting, using a DIG-DNA detection kit (Roche 
Molecular Biochemicals), according to the manufacturer instructions, with minor 
modifications. In situ hybridization was performed, using Ogata’s technique with 
certain modifications [32]. Paraffin sections were deparaffinized, rehydrated, and 
submitted to microwave in the presence of 10 mM MgCl2 buffer (pH 6) for 5 min 
at 750 W. Sections were allowed to cool down for 20 min and then digested with 
20 μg/ml proteinase K for 10 min at 37°C. They were then fixed in paraformaldehyde 
in 0.1 M phosphate buffer containing 50% formamide, 10 mM Tris-HCl (pH 7.6), 
200 μg/ml tRNA, 1 x Denhardt’s solution, 10% dextran sulphate, 600 mM NaCl, 
0.25% SDS, and 1 mM EDTA, pH 8.0. Hybridized DIG-labeled probes were detected 
by the DIG-Nucleic Acid Detection kit (Roche Molecular Biochemicals), followed 
by blocking with 1.5% of the blocking reagent included in the kit. The color reac-
tion was stopped with 10 mM Tris-HCl (pH 7.6) and 1 mM EDTA. Sections were 
then fixed in 4% paraformaldehyde in phosphate-buffered saline and stained with 
hematoxylin. In addition to the neuroblastoma cell lines used as positive and nega-
tive controls, CHL cases negative for MV by IHC and NHL served as controls.
2.4 Comparison between IHC, RT-PCR, and ISH
This was performed on a sampling of cases. For this purpose, IHC positivity to a 
single NP-MV or HA-MV antibody was considered sufficient.
2.5 Clinicopathological correlations
Emphasis was given to MV IHC and to EBV-LMP1 expression, as RT-PCR and 
ISH disclosed much less results. For contingency table analysis, the χ2 or Fisher’s 
exact test was used as appropriate.
3. Preliminary results
The lymph node tissues of 82 of 154 CHL patients were positive for at least two 
MV antigens (Figure 3). Neutralization of immunostaining was made possible by 
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incubation of the primary anti-NP-MV antibody with the corresponding NP-MV 
peptide (Figure 3b). This assay confirms the specificity of the anti-NP-MV anti-
body in this context. Twenty-five cases of non-Hodgkin lymphoma (NHL) were 
totally negative for MV antigens.
A Southern blotting of the nested PCR shows several bands, some stronger, 
others faint, disclosing more hemagglutinin (HA, H) MV positivity, as compared 
with NP-MV positivity (Figure 4). Samples from 7 NHL were negative. Thus, in our 
laboratory, HA-MV RNA was positive in 4 of 15 cases, while only 2 of 16 NP-MV 
RNAs were expressed by the Southern blot in CHL.
Upon sequencing and alignment of three of the experiment products, we 
displayed an almost complete homology with the control (see [3] for details on the 
homology).
In situ hybridization on paraffin sections shows a strong cytoplasmic staining 
in the positive control (persistently MV infected murine neuroblastoma cell line) 
(upper left). The same cell line uninfected by MV was negative. An H/RS cell shows 
strong cytoplasmic positivity with NP-MV (lower left). Positive granular staining 
of several H/RS cells is disclosed in the right lower quadrant (Figure 5). Altogether, 
2 of 7 CHL sections submitted for ISH were positive for HA-MV RNAs, while 8 of 21 
were positive for NP-MV RNAs.
Figure 3. 
Classic Hodgkin lymphoma-nucleoprotein-MV expression. a. Positive cytoplasmic immunostain of Hodgkin/
Reed-Sternberg cells. b. Immunostaining following neutralization of antibody with a relevant MV peptide 
(Immunoperoxidase with DAB × 320).
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Figure 4. 
Southern blotting based on cDNA from RT-PCR: A. A few cases of CHL show bands positive for 
hemagglutinin-MV (PC—positive control). B. Isolated bands, positive for nucleoprotein-MV. C and D. Absence 
of expression of MV in non-Hodgkin lymphomas.
Figure 5. 
In situ hybridization with MV-RNA. a. Positive control, using a murine, MV-transfected cell line. b. Negative 
control, with a non-transfected cell line. c. A Hodgkin/Reed-Sternberg cell disclosing positive cytoplasm for 
MV-NP-RNA. d. H/RS cells showing a granular cytoplasmic positivity for MV-HA-RNA.
Viruses
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A clinicopathological correlation was based on the immunophenotypic find-
ings, as the specificity of the antibodies had been sustained by Western blotting 
and since, in each case, the immunostain had been confirmed with more than two 
antibodies. Last, the immunohistochemical (IHC) study had released the most 
manageable results.
Table 1 shows a statistically significant expression of MV antigens in female 
patients, in nodular sclerosis (NS) CHL, as compared with mixed cellularity (MC) 
CHL. A significant correlation was exhibited between negative CD15 and p53, and 
the negative expression of MV. Table 2 displays a statistically significant expression 
of MV antigens compounded by the expression of EBV/LMP1, in NS-CHL, signifi-
cantly more than that in MC-CHL, in early clinical stages, with apoptotic index 
lower than median and with the positive expression of MDM2.
A multivariable logistic regression model of the association of prognostic factors 
with dying from CHL, in 89 patients, is shown. Stage IV, as compared with the remain-
der, carried a significantly poorer prognosis, thus confirming that our cohort was 
representative. The compound expression of MV and EBV, specifically of MV+; EBV−, 
as well as MV−; EBV− was displayed as poor risk factors in our patients (Table 3).
MV+; LMP− MV−; LMP+ p Value
Subtype NS 45 (86.5) 7 (13.5) 0.00008
MC 11 (44) 14 (56)
Stage I–IIA 22 (84.6) 4 (15.4) 0.023
IIB–IVB 22 (57.9) 16 (42.1)
BCL-2 Pos. 31 (93.9) 2 (6.1) 0.0001
Neg. 27 (54) 23 (46)
MDM-2 Pos. 36 (87.8) 5 (12.2) 0.0013
Neg. 18 (54.5) 15 (45.5)
Apop index <Median 31 (81.6) 7 (18.4) 0.024
>Median 22 (42.1) 16 (57.9)
Table 2. 
Hodgkin lymphoma—association with measles and Epstein-Barr viruses.
MV+ MV− p Value
n (%) n (%)
Total 82 (54.3) 69 (45.7)
Gender F 40 (64.5) 28 (35.5) 0.036
M 42 (47.2) 47 (52.8)
Subtype NS 58 (68.2) 27 (31.8) 0.0013
MC 21 (40.4) 31 (59.6)
CD15 pos 77 (59.7) 52 (40.3) 0.015
neg 4 (26.7) 11 (73.3)
p53 pos 72 (61.5) 45 (38.5) 0.017
neg 5 (31.3) 11 (68.8)
Table 1. 
Associations of classic Hodgkin lymphoma with the measles virus.
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4. Interim discussion
The results of the first part of our study (2004) are summarized [3]. The association 
between MV and CHL, in a descriptive investigation, does not contain, so far, causal 
elements. This linkage is sustained by older epidemiologic studies describing brain and 
spinal cord tumors, as well as CHL, which followed exposure to the MV around the time 
of birth [33, 34]. They also suggest sporadic cases of CHL regression, occurring after 
acute measles infection or an MV vaccine [35–38]. Moreover, viral childhood infections, 
including measles, have been reported to protect from CHL occurrence [39].
Early clinical correlations exhibit more females, more NS-CHL, and more early 
stage cases, among patients with positive MV expression in their lymph node tis-
sues. Nevertheless, positive MV expression in CHL seems to be related with a worse 
prognosis. One cannot refute the loss of the advantage conferred to the above vari-
ables by an MV infection, as expressed in the H/RS cells of CHL. Any mechanism 
involving the MV in CHL, if uncovered, should correlate with a worse outcome of 
the malignancy.
5. The refutation episode
Two years following the publication of the above-mentioned article and several 
months after the presentation of a poster at the Hodgkin Lymphoma Meeting in 
Kiel, a scientist, from Germany, contacted me indirectly, informing me that he 
wanted to investigate our findings. He proposed to find out whether he could repro-
duce our data in his lab. He also requested to make any fresh-frozen CHL tissues 
available to him, mainly those which showed an MV-antigen positivity.
In their labs, the German scientists had collected 44 frozen CHL samples, of 
which, only 18 were selected for their high quality RNA, as determined by the 
Agilent technology, as well as for classic H/RS cell morphology. Using UV-laser 
beam single cell microdissection, some 100 H/RS cells were pooled for each experi-
ment. Total RNA was extracted and RT-PCR was performed with primers from 
three MV genes, which were different from those we had used in Israel [40].
Five CHL-derived cell lines were found to be negative for the three MV tran-
scripts. Moreover, the 18 selected German cases did not show, either, evidence of 
any of the three viral transcripts. The GAPDH gene, used as a housekeeper gene 
for these experiments, displayed a large amount of RNA. At this point, the German 
group had received the 22 snap-frozen CHL samples from our laboratory. The cases 
had been chosen, as requested for their positive MV antigens, as shown on FFPE 
tissues. However, the selection highlighted only 7 of these cases, chosen for the high 
RNA quality and the classic H/RS cell features [40].
Factor Odds ratio 95% CI p Value
Gender 1.32 0.34–5.18 0.69
Stage 13.67 2.3–80.5 0.004
Bcl-2 0.34 0.08–1.44 0.34
MV+; EBV− 10.05 0.98–103.47 0.05
MV−; EBV+ 1.53 0.07–35.44 0.79
MV−; EBV− 15.2 1.05–220.3 0.04
Table 3. 
Multivariable logistic regression model of association of prognostic factors with dying of HL in 89 patients.
Viruses
10
All 25 RNA samples disclosed negative results with the three MV transcripts, as 
studied in Essen labs. Back to Israel, 5 of 12 German histological unstained slides, 
subjected to IHC, were found to express MV antigens in the H/RS cells. A similar 
discrepancy in favor of IHC was also obtained in our series (Table 4).
The German scientists invited one of my colleagues and myself to co-author 
their manuscript. At every stage, we were reluctant to accept the invitation, due to 
the concern for a permanent damage to our hypothesis. Moreover, we did not curb 
our criticism, which covered several aspects of the manuscript. Prominent among 
these was the tight selection of the cases (both those from Germany and Israel). The 
methods used in Essen differed markedly from ours, notably the single cell micro-
dissection, a different strategy for the RT-PCR and the choice of primers. Following 
our criticism, minor changes were introduced, but the German group did not go all 
the way: “….due to their worry that the manuscript will lose its sharp edge and might 
not be accepted by a highly rated journal.”
The Scott collaborators of the Essen scientists reported above selected a group 
of patients, many of whom having suffered from measles, mainly as children. We 
consider this selection as counterproductive, since these patients should have been 
protected from the development of CHL. The very fact that they were not refutes the 
prevalent thesis that exposure of a child, aged 1–4 years, to MV infection protects the 
subject from CHL at a young-adult age [41]. The Scottish group may have had their 
own agenda, which might have unsettled the question raised by us. In addition, the 
antibody used by the Scott group is problematic: the clone 49–41 was purchased by us 
from Argene-Biosoft, Varilhes, France (# 11-045). It was not an anti-nucleoprotein 
antibody, as stated, and was positive in our lab for 37 of our 72 CHL cases (data not 
shown). Moreover, not unlike the German scientists, the Scotts used the GAPDH gene 
as a housekeeping gene, and we have already mentioned why it was not appropriate.
I have to admit, that we not only considered ourselves as the minor partner, 
but that we were such indeed! We had been recurrently reassured by the German 
scientists and by then had our two names included in the manuscript as co-authors. 
However, when we read the finalized doublet articles (in addition, the article by 
Wilson et al., weighted heavily on the balance) [41], published in the International 
Journal of Cancer, we realized that we had made a huge mistake.
The days which followed the double publication were crucial, since we were not 
sure, as co-authors, whether we were entitled to carry out an “insider” censure. When 
we read the final paper, we grasped the experience in terms of a possible deception. In 
addition to the impediments mentioned above, we also noted that the housekeeping 
gene, the GAPDH, might not be an adequate choice at all, since we had shown that 
CHL is most probably of low MV-RNA abundance. In contrast, the Essen group had 
described in relation with GAPDH a large amount of RNA [40]. Moreover, of the 
seven Israeli cases, selected for the experiment in Germany, five had been shown by 
us to present a faint MV-RNA positivity only (two) or were negative (three).
NP-MV HA-MV
Positive/n (%) Positive/n (%)
RT-PCR 1/16 (6.25) 7/21 (33.3)
ISH 7/14 (50) 4/7 (57.1)
IHC 25/29 (86.2) 20/29 (68.9)
NP, nucleoprotein; HA, hemagglutinin; MV, measles virus; RT-PCR, reverse transcriptase-polymerase chain reaction; 
ISH, in situ hybridization; and IHC, immunohistochemistry.
Table 4. 
Comparison of results obtained by three assays.
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An independent putative evidence for a role of the MV in carcinogenesis is that 
part of the MV proteins that interacts with and stabilizes the Pirh2 protein, an ubiq-
uitin E3 ligase, by preventing its ubiquitination. Pirh2 indeed negatively regulates 
p53 by targeting it for degradation in the proteasome.
Altogether, our criticism of the article, in which we took officially a part, is in 
principle that the German scientists carried out an investigation, which was by their 
declared intention, a duplication of our own research [3]. However, their study was 
anything, except a duplicate of ours! It stands out independently, with major flaws, 
notably a very strong selection of cases, the use of questionable primers of a housekeep-
ing gene which is not appropriate for the expected amount of retrieved MV-RNA. It is 
of note that when confronted with our criticism regarding the manuscript, the German 
group seemed to agree, but did not modify the manuscript: “…for fear of weakening our 
data”. Moreover, they insisted on mentioning the relevance of the findings to the CHL 
pathogenesis, which was not appropriate at this stage nor was it agreed upon [40]!
At this point, we insist that the impact of the European group refutation, on 
a possible role of MV in CHL, was extremely ruinous to our position and thesis. 
Moreover, its repercussions are felt to this day: for the reasons mentioned above, not 
a single investigator has accepted to engage in this project anymore, together with us 
or independently. By so doing, the two research groups have categorically “buried” 
our hypothesis. At the same time, we felt a release from the constraints which might 
have led us freeze in our position and we allowed ourselves again to indulge in the 
research concerning the measles virus and cancer. Therefore, we first wrote a review 
on our experience, as described above [42, 43].
6. New evidence
We set out to delve into endometrial carcinoma (EC), looking for the footprints 
of the MV in this cancer. Our cohort of EC included 49 patients, 36 of whom had 
a known follow-up. Using IHC and several anti-MV antibodies, we disclosed that 
26 of the 36 (72%) did express MV antigens in tumor cells, mainly in type I EC 
(Figure 6). In addition, 16/21 of the patients displayed positivity for MV-RNA by 
ISH. When type II EC was allied with MV, then deeper myometrial invasion and a 
higher mortality were evident [44].
Our next endeavor concerned the possible role of MV in lung cancer. Our interest 
was first raised by the probable relevance of Pirh2 in lung cancer. Indeed, Pirh2, an 
E3 ubiquitin ligase, was found to be expressed in lung cancer, in which it inhibits p53 
[45]. It was later found that the P-protein of the MV inhibited the function of Pirh2 
(see description in [48]). This indirect association between lung cancer, Pirh2 and p53, 
and MV led us to the following study. We identified 65 non-small cell lung cancers, 
for which FFPE tissues were available over 10 years. We limited our study to the IHC 
analysis with several anti-MV antibodies (Figure 7). Of the cases included, 54/65 were 
positive for MV antigens. These 54 positive cases were associated with older patient 
age, with positive Pirh2 expression, as well as with an improved survival [46].
The following study concerned breast cancer and the MV-IHC expression. We 
identified 131 breast cancer cases, with preserved FFPE tissues. Of these cases, 64% were 
positive for the MV antigens (Figure 8). Positive MV expression was associated with ER 
(p = 0.018); with Ki-67 < 40% (p = 0.029); with low or intermediate grade (p = 0.037); 
with age < 50 (p = 0.039); and with p53 overexpression (p = 0.049) (Table 5). It seems, 
therefore, that the MV may play a role in the development of this cancer [47].
We have speculated whether the MV phosphoprotein, through its relation with 
the Pirh2, ubiquitin ligase, by itself negatively related with the p53 expression, may 
have more relevance, a priori, than other MV antigens to the pathogenesis of the 
Viruses
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MV-associated cancer [48]. We therefore purchased a robust anti-MV-phosphopro-
tein antibody (9H4): sc-101,356, Santa Cruz Biotechnology, and used it by Western 
blot, first, to determine whether we could find a variance between the different 
types of lung cancers and in addition to determine whether the normal lung tissues 
around the tumor did express the MV. But, the distribution of lung cancer types in 
our cohort was clearly in favor of adenocarcinoma, which expressed the P-MV in 11 
patients (84.6%). This was also the rate of its expression in the normal lung tissue 
Figure 7. 
Lung cancer—positive for MV. a. Adenocarcinoma. b. Squamous cell carcinoma (IHC with DAB × 240).
Figure 6. 
Endometrial carcinoma—MV expression in tumor cells and in normal endometrium. a. Cytoplasmic HA-MV 
antigen is positive. b. Positive immunostain for NP-MV antigen. c. ISH positivity for NP-MV in tumoral 
glands. d. ISH positivity of surface and glandular normal epithelium of the case shown in c.
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Figure 8. 
Breast cancer is positive for measles virus antigens. a and c. Negative controls. b and d. Positive immunostains 
(immunoperoxidase with DAB × 180).
Variable Variable distribution
Demographics
Age <50 years >50 years
Ethnicity Jewish Bedouin-Arab
Birth place Israel/Europe/America Asia/Africa
Pathology
Tumor diameter <10 mm >10 mm
Axillary LNs None Involvement
DCIS component Yes No
Grade Low/intermediate G1–2 High G3
Immunohistochemistry
ER Positive Negative
PR Positive Negative
HER2 Positive Negative
Ki67 Positive Negative
p53 Positive Negative
NP-MV Positive Negative
HA-MV Positive Negative
Table 5. 
Distribution of demographics, clinics, pathology, and MV expression in breast cancer patients.
Viruses
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(Table 6; Figure 9). The second step was to look for the expression of the P-MV in 
a tissue microarray (one tissue microarray slide). We compared 10 lung cancers, 13 
colon cancers, 14 stomach cancers, and 15 breast cancers. Breast cancer expressed 
the MV antigen in 75% in the nucleus and 50% in the cytoplasm. Stomach cancers 
expressed the antigen in 73.7% in the nucleus and 21% in the cytoplasm. Colon 
cancers expressed the MV in 68.4% in the nucleus (Table 7). The tissue microar-
ray study had demonstrated a nuclear expression of MV antigens, of which we 
have not been aware before. This may be due on the one hand to the tiny size of 
the tissue section. On the other hand, it may be specific to the present anti-P-MV 
antibody. In any case, various immunostains have shown a marked shuttling of 
antigens between cytoplasm and nucleus in various tissue sections and with varied 
antigens [49] (Table 7).
Our experience with melanoma and benign melanocytic nevi is shown in 
Table 8. The table shows the expression of several MV antigens and of Pirh2. The 
expression of NP-MV is the strongest and resembles that of Pirh2. A similar trend, 
but with a more limited expression, is found in benign melanocytic nevi. It is of 
note that the expression of the P-protein in melanomas is the mirror image of that 
of the NP-MV antigen. This was a preliminary exercise and no follow-up is yet 
Pathology Positive (%) Negative (%)
Adenocarcinoma 11 (84.6%) 2 (15.4%)
Squamous cell carcinoma 3 (100%) 0
Large cell carcinoma 1 (100%) 0
Bronchioloalveolar carcinoma 1 (100%) 0
Table 6. 
Western blotting using a phosphoprotein-MV antibody.
Figure 9. 
Western blotting with an antiphosphoprotein-MV antibody on fresh frozen tissues of non-small cell lung cancer. 
Most cases show positive expression both in tumor tissue (T) and in nonadjacent nonneoplastic lung tissue (H). 
In a few cases, the MV expression is found in the tumor only.
Positive staining % Negative staining %
Organ Nucleus Cytoplasm Stroma Nucleus Cytoplasm Stroma
Lung 10 (52.6%) 2 (11.1%) 0 9 (47.4%) 16 (88.9%) 18 (100%)
Colon 13 (68.4%) 7 (36.8%) 4 (23.5%) 6 (31.6%) 12 (63.2%) 13 (76.5%)
Stomach 14 (73.7%) 4 (21%) 0 5 (26.3%) 15 (79%) 19 (100%)
Breast 15 (75%) 10 (50%) 2 (10%) 5 (25%) 10 (50%) 18 (90%)
Table 7. 
Tissue microarray using a phosphoprotein-MV antibody.
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available. The positivity of 23 benign nevi for NP-MV should be investigated to 
exclude evidence of a pre-malignant condition.
At this stage, we were motivated to determine whether some categories of 
tumors might be uniformly negative for MV antigens. One limitation is that these 
tumors were often showed with a restricted sampling. In our original study, we 
included 25 NHLs by IHC and 7 cases of non-Hodgkin lymphoma by RT-PCR. They 
were all negative for MV. Only later did we find an interest in ALK-positive ana-
plastic large cell lymphomas in this regard. In contrast, these lymphomas were 
predominantly positive for MV. A large scale study of seminomas showed negativ-
ity for the MV antigens. Glioblastomas and mesotheliomas were negative for the 
antigens (Samuel Ariad, personal communication). I later examined small samples 
of the following tumors which were also negative for the MV antigen: Merkel-cell 
tumors, hepatocellular carcinoma, malignant mixed mesodermal tumors, and 
desmoid tumor.
In 2010, we revised and expanded a prior study on the role of apoptosis in CHL 
[50, 51]. This was undertaken in the light of a consensual point of view: it has 
been stated that apoptosis in CHL is arrested; this is carried out not only with the 
help of the NF-κB machinery but also through the expression of EBV-LMP1 that 
inhibits apoptosis [52–55]. The consensus further determines that this apoptosis 
hindrance is necessary, since tumor cells in CHL are B cells which cannot express 
the B-cell receptor (in physiologic conditions, such cells have a strong tendency 
to die in apoptosis). Thus, apoptosis inhibition is a pre-condition for the survival 
of H/RS cells [56]. However, in our revision, we found inhibition of H/RS cells 
apoptosis in 55% of the 217 cases only. Our findings also suggested that NF-κB, 
specifically the p65 protein, as well as EBV/LMP1 expression did not correlate 
with apoptosis arrest, in contrast with the consensus view [57]. Of note, it has 
been shown that although the presence of canonical NF-κB has been considered 
to be implied, it is the noncanonical NF-κB, which is of predominant relevance 
in CHL [51]. In the revision we have shown that the most significant association 
of H/RS cell apoptosis was with p53, the negative expression of which was related 
with a high apoptotic index (p = 0.001). We looked for a link between positive MV 
expression and factors related with apoptosis. Associations with apoptotic index 
less than median (p = 0.005), with MDM2-positive (p = 0.028) and with IκB-
positive (p = 0.0001), were displayed. Viruses have a propensity to regulate the 
apoptotic mechanisms of the infected cell. We have hereby proposed a pathogenic 
mechanism, involving the MV and that is effective in the modulation of apoptosis, 
at least in CHL [51].
Antigen Level Melanoma Benign nevi P value
NP-MV Pos. 46 23
Neg. 10 1 0.16
P-protein Pos. 19 10
Neg. 36 12 0.37
HA-MV Pos. 19 7
Neg. 3 1 1.00
Pirh-2 Pos. 44 19
Neg. 12 6 0.79
Table 8. 
Melanoma and measles virus.
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7. The atypical measles syndrome
In contrast with the classic measles infection, the atypical measles syndrome 
occurs in older patients, often presenting with a heterogeneous rash, pulmonary 
infiltrates, hepatic dysfunction, and eosinophilia. The formation of immune 
complexes has been proposed as responsible for the manifestations of the syndrome 
[58]. This self-limiting disease, may show, however, long lasting, asymptomatic pul-
monary nodules. An immune waning is suspected to occur in this disorder, though 
such an event has been refuted with measles virus infection at large. Officially, 
patients with this syndrome have been reported as recently as 2015 [59].
The atypical measles syndrome (AMS) stands out when compared with classic 
measles for the following reasons.
AMS presents at an older age, often with a high and prolonged fever. A poly-
morphic rash starts in the hands and feet. In the lungs, this disorder shows nodular 
infiltrates together with swollen hilar lymph nodes. These changes may regress 
suddenly. Liver function tests are often abnormal in AMS. Eosinophilia is frequent. 
This disease entity was first described in 1963, following the vaccination with the 
formalin inactivated measles virus (FIMV) vaccine. A subsequent exposure to the 
wild type MV has often been identified. The FIMV vaccine is said to have been 
withdrawn in 1967, but new cases of AMS were still reported in 2015 [59].
Clinically, the AMS does not resemble the classic MV disease and is usually mild. 
GPs have difficulties in making the diagnosis in real time. Anti-MV antibody titers 
are higher than 1:160, which is very unusual for classic measles. In AMS, Koplik 
spots are frequent and mostly will last 5–7 days, while they last rarely more than 
2 days in the classic disease. Photophobia is rarely present in AMS. AMS is probably 
not contagious [60].
While most cases of AMS in the 1960s were associated with FIMV, the more 
recent occurrences have been associated with the live attenuated measles vaccine 
(LAV). Vaccination with FIMV had offered protection for a few months, after 
which the titers dropped suddenly [61]. We have suggested that this drop of anti-
body titers is most consistent with a humoral immunity waning. Cases of AMS with 
prior LAV vaccine have been reported, which are consistent with secondary vaccine 
failure. Such cases have been suggested to follow a prolonged exposure to an acute 
measles patient [62].
To confirm the ease by which the diagnosis of AMS is missed, 291 recruits were 
diagnosed with measles in 1987. They were young adults, with abdominal pain, 
diarrhea, and vomiting (33%); Koplik spots lasting a mean 7 days; and abnormal 
liver function tests (86%). The diagnosis of AMS was missed. Retrospectively, 
this was most certainly the diagnosis, although no anti-MV titers have been 
reported [63].
In 2015, Levine et al. reported on the status of the measles immunity, 20 years 
after the two-dose MMR vaccine was introduced. Of the cohort of recruits in 1996, 
95.6% had shown positive anti-MV antibodies. In 2007, this positive data had 
dropped to 85%. Although the authors did not dare to make the statement, this 
reflected a state of waning immunity, to our opinion [64].
To summarize this issue, we have showed that the AMS differs from typical 
measles by various features. This is probably a disorder of immunologic nature, 
involving immune complexes. The AMS is presently rare, but to our opinion, 
this may be due to a notable under-diagnosis. The association between the AMS 
pathogenesis and immune waning should be confirmed. It is not excluded that this 
disorder be related with carcinogenesis as well [65, 66], as it has been proposed that 
a persistent viral infection is required for virus-associated carcinogenesis [67] and 
that a waning immunity might lead to a persistent MV infection.
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8. Conclusions and prospects
A relationship between MV expression and CHL was provisionally established 
on IHC [positive with two antigens or more in 82 of 154 CHL patients]; on RT-PCR 
[positive in 4 of 15 cases for HA-MV RNA; for 2 of 16 NP-MV RNA], and on in situ 
hybridization [for 2 of 7 CHL with HA-MV RNA; in 8 of 21 for NP-MV RNA], as 
well as with several other malignancies. When focusing on CHL, this association 
may even be causally linked: apoptosis regulation by the MV may be one of the 
supportive mechanisms. Our findings are probably sustained by an increasing CHL 
morbidity related with a progressing occurrence of measles in young adults, in 
Israel [68], in Quebec [69], and in Connecticut [70], in which frequent outbursts of 
measles are described.
A clinicopathological correlation, based on the IHC results, was chosen, mainly 
due to the frequent results as compared with RT-PCR and in situ hybridization. In 
this part of our study, we confirmed an association between CHL and the MV. More 
females, NS-CHL cases, and more patients in the early stages of their disease were 
linked to the expression of MV in their tissues. In spite of these variables being, as 
a rule, correlated with a better prognosis, when they are associated with a positive 
measles expression, the net effect is a poor prognosis [3].
Regarding the refutation of our findings and conclusions by the German group, 
this might have been an occasion for further learning. However, the repercussions 
thereof, on our thesis and our findings, were such that no future was available for 
us in this domain. As a colleague described it, our position and our theory had been 
buried. Moreover, I never understood why it was done in that most unpleasant way.
A chapter on the atypical measles syndrome was introduced at the end of the 
study. This disorder is related with measles and with the MV, but the link has not 
been clarified completely. Most of the AMS features, clinical, radiological, and bio-
logical, differ completely from those of measles. While measles is predominantly an 
infectious disease, and is highly contagious, AMS is probably not contagious, with 
its pathogenesis probably based on the formation of immune complexes. One of 
the highlights of the AMS is an anti-measles antibody titer of 1:160 or higher, much 
beyond that found in measles. Our interest, at this point, laid in evidence pointing 
toward immunity waning, as an essential component of AMS. Moreover, in the 
presence of a sharp drop in the titer, following mainly the FIMV vaccination, as 
well as occasionally that of the LAV vaccine, the subject might be submitted to the 
protracted exposition to an acute measles patient. So far, we are not aware of cancer 
developing in the context of AMS cases, but, since this disorder is often missed, it 
might be worthwhile looking for cases of cancer within such a context [60].
The prospects and suggestions for proceeding with our research include an epide-
miologic study as well as the duplication of our basic investigation, but this once by 
scientists of good faith. The epidemiologic investigation should have 3 components: 
the first two, based on our CHL cohort, about half of which show IHC evidence of the 
MV. Of this population, we will attempt to identify, via the Israeli Ministry of Health 
Registry, patients who had contracted measles as well as those who had been vac-
cinated for MV, including vaccination details. The third will deal with AMS, based on 
the cohorts highlighted by Giladi M et al. [63], and Levine H et al. [64]. Confirmation 
in the first of the diagnosis of AMS, and research of patients with possibly MV-related 
tumors and in the second, confirmation of the relevance to immune waning.
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